WallStSmart

Novartis AG ADR (NVS)vsRockwell Medical Inc (RMTI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 81592% more annual revenue ($56.58B vs $69.26M). NVS leads profitability with a 23.9% profit margin vs -7.7%. NVS appears more attractively valued with a PEG of 2.48. NVS earns a higher WallStSmart Score of 51/100 (C-).

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 4.0Quality: 5.5
Piotroski: 4/9Altman Z: 1.96

RMTI

Avoid

33

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-52.5%)

Margin of Safety

-52.5%

Fair Value

$109.60

Current Price

$147.85

$38.25 premium

UndervaluedFair: $109.60Overvalued
RMTIUndervalued (+88.6%)

Margin of Safety

+88.6%

Fair Value

$8.93

Current Price

$0.88

$8.05 discount

UndervaluedFair: $8.93Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$282.11B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

RMTI1 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Areas to Watch

NVS4 concerns · Avg: 3.0/10
PEG RatioValuation
2.484/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

RMTI4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$35.07M3/10

Smaller company, higher risk/reward

PEG RatioValuation
4.432/10

Expensive relative to growth rate

Return on EquityProfitability
-15.3%2/10

ROE of -15.3% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bull Case : RMTI

The strongest argument for RMTI centers on Price/Book.

Bear Case : NVS

The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.

Bear Case : RMTI

The primary concerns for RMTI are EPS Growth, Market Cap, PEG Ratio.

Key Dynamics to Monitor

NVS profiles as a declining stock while RMTI is a turnaround play — different risk/reward profiles.

RMTI carries more volatility with a beta of 1.71 — expect wider price swings.

NVS is growing revenue faster at -0.7% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (51/100 vs 33/100), backed by strong 23.9% margins. RMTI offers better value entry with a 88.6% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Rockwell Medical Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Rockwell Medical, Inc. is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with iron deficiency treatment and hemodialysis products and therapies in the United States and internationally. The company is headquartered in Wixom, Michigan.

Want to dig deeper into these stocks?